Enanta Pharmaceuticals
ENTA
127 hedge funds and large institutions have $598M invested in Enanta Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 50 increasing their positions, 36 reducing their positions, and 12 closing their positions.
238% more call options, than puts
Call options by funds: $1.44M | Put options by funds: $426K
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
39% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 36
32% more capital invested
Capital invested by funds: $454M → $598M (+$144M)
4% more funds holding
Funds holding: 122 → 127 (+5)
0.83% more ownership
Funds ownership: 66.11% → 66.95% (+0.83%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$25M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$16.6M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$8.04M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.12M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$3.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$17.5M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$7.2M |
| 3 |
AC
Armistice Capital
New York
|
-$6.27M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.11M |
| 5 |
KAM
Krensavage Asset Management
New York
|
-$3.66M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GTC
126
Ghost Tree Capital
New York
| – | -$7.2M | -200,000 | Closed |
|
|
IG
127
ING Group
Amsterdam,
Netherlands
| – | -$3.27M | -91,000 | Closed |
|
128
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$2.89M | -71,815 | Closed |
|
|
SIM
129
Spark Investment Management
New York
| – | -$1.91M | -53,100 | Closed |
|
|
CLOS
130
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| – | -$1.51M | -42,000 | Closed |
|
|
BCM
131
Bridgeway Capital Management
Houston,
Texas
| – | -$720K | -20,000 | Closed |
|
|
TI
132
Telemetry Investments
New York
| – | -$223K | -6,200 | Closed |
|
133
Tudor Investment Corp
Stamford,
Connecticut
| – | -$209K | -5,802 | Closed |
|
134
Simplex Trading
Chicago,
Illinois
| – | -$199K | -4,953 | Closed |
|
|
GH
135
GAM Holding
Zurich,
Switzerland
| – | -$108K | -3,000 | Closed |
|
|
GI
136
Gradient Investments
Arden Hills,
Minnesota
| – | -$10K | -268 | Closed |
|
|
CG
137
Cutler Group
San Francisco,
California
| – | -$7.48K | -186 | -93% |
|
|
WAM
138
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| – | +$80 | +2 | New |
|
ENTA Hedge Fund Activity: Q3 2017 in Review
127 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2017, worth a combined $598M — up 32% from $454M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ENTA positions and 12 closed out — a net gain of 7 holders — while 50 added to existing stakes and 36 trimmed.
The largest buyer was Invesco, adding an estimated $25M. The largest seller was Millennium Management, exiting entirely with an estimated $17.5M sold.
- 127 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2017, up from 122 in Q2 2017.
- Funds reported $598M of Enanta Pharmaceuticals stock for Q3 2017, up 32% quarter-over-quarter.
- 19 funds opened new Enanta Pharmaceuticals positions in Q3 2017 and 12 closed out, a net change of +7 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2017 was Invesco, an estimated $25M added.
- The largest Enanta Pharmaceuticals seller in Q3 2017 was Millennium Management, an estimated $17.5M sold.
Based on aggregated 13F filings for Q3 2017.